Mass Switch From Intravenous to Subcutaneous Tocilizumab in Rheumatic Diseases During the SARS-COV-2 Pandemic.

MLA

Cáceres, Vicente Aldasoro, et al. “Mass Switch From Intravenous to Subcutaneous Tocilizumab in Rheumatic Diseases During the SARS-COV-2 Pandemic.” Journal of Clinical Rheumatology : Practical Reports on Rheumatic & Musculoskeletal Diseases, vol. 28, no. 7, Oct. 2022, pp. 346–48. EBSCOhost, https://doi.org/10.1097/RHU.0000000000001862.

APA

Cáceres, V. A., Piñeiro, M. L., Ibáñez-Beróiz, B., & Enguita-Germán, M. (2022). Mass Switch From Intravenous to Subcutaneous Tocilizumab in Rheumatic Diseases During the SARS-COV-2 Pandemic. Journal of Clinical Rheumatology : Practical Reports on Rheumatic & Musculoskeletal Diseases, 28(7), 346–348. https://doi.org/10.1097/RHU.0000000000001862

Chicago

Cáceres, Vicente Aldasoro, María Laíño Piñeiro, Berta Ibáñez-Beróiz, and Mónica Enguita-Germán. 2022. “Mass Switch From Intravenous to Subcutaneous Tocilizumab in Rheumatic Diseases During the SARS-COV-2 Pandemic.” Journal of Clinical Rheumatology : Practical Reports on Rheumatic & Musculoskeletal Diseases 28 (7): 346–48. doi:10.1097/RHU.0000000000001862.